phase 2 trial – Medxy AI

Litifilimab Shows Promising Efficacy and Safety in Treating Cutaneous Lupus Erythematosus: Insights from the AMETHYST Phase 2 Trial

By MedXY 10/24/2026

The AMETHYST Phase 2 trial demonstrated that litifilimab significantly improves skin symptoms in cutaneous lupus erythematosus with a favorable safety profile, marking a potential new targeted treatment for this challenging condition.

Hematology-Oncology news

CPX-351 versus CLAG-M in Medically Unfit Adults with AML: A Phase 2 Randomized Study Evaluating Survival and Response Outcomes

By MedXY 09/20/2026

This phase 2 trial compares CPX-351 with CLAG-M chemotherapy in medically unfit adults with AML, finding CLAG-M achieves better 3-month survival and response rates, especially in patients with proliferative disease, suggesting intensive therapy benefits select subgroups.

news Oncology Radiology

Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcoma: Long-Term Results From the DOREMY Phase 2 Trial

By MedXY 06/10/2026

Long-term follow-up from the DOREMY phase 2 trial shows that reduced-dose preoperative radiotherapy for localized myxoid liposarcoma achieved excellent local control with relatively low toxicity.

news Oncology Radiology

Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcoma: Long-Term Results from the Phase 2 DOREMY Trial

By MedXY 06/10/2026

A long-term phase 2 trial found that reduced-dose preoperative radiotherapy followed by surgery provided excellent local control and acceptable toxicity in localized myxoid liposarcoma.

Diabetes & Endocrinology news

Phase 2 Study of XP-8121: Once-Weekly Subcutaneous Levothyroxine for Adult Hypothyroidism

By MedXY 06/05/2026

A Phase 2 trial found that once-weekly subcutaneous levothyroxine (XP-8121) was generally well tolerated and suggested a dose conversion of about four times the daily oral dose for adults with hypothyroidism.

Hematology-Oncology news Otorhinolaryngology

Amivantamab Falls Short of Tumor Shrinkage in Recurrent or Metastatic Adenoid Cystic Carcinoma, but Disease Stabilization Was Common

By MedXY 04/20/2026

In a phase 2 trial, amivantamab did not meet its primary response endpoint in recurrent/metastatic adenoid cystic carcinoma, but most patients achieved stable disease and toxicity was generally manageable.

Hematology-Oncology news

CM313, a Novel Anti-CD38 Monoclonal Antibody, Demonstrates Promising Efficacy and Safety in Persistent or Chronic Primary Immune Thrombocytopenia: Insights from a Phase 2 Randomized Trial

By MedXY 10/31/2025

The phase 2 trial shows that CM313 significantly improves platelet response rates and duration with manageable safety in adults with persistent or chronic primary immune thrombocytopenia.

Gastroenterology news Oncology

Conversion Therapy with Tislelizumab, Lenvatinib, and GEMOX in Unresectable Locally Advanced Biliary Tract Cancer: The ZSAB-TransGOLP Phase 2 Study

By MedXY 10/15/2025

The ZSAB-TransGOLP study demonstrates the promising efficacy and manageable safety of combining tislelizumab, lenvatinib, and GEMOX chemotherapy as a conversion therapy for unresectable locally advanced biliary tract cancer, achieving a 63% R0 resection rate.

Clinical Updates Hematology-Oncology news Specialties

Advancing Care in Older Adult T-Cell Leukemia/Lymphoma: Phase 2 Trial of Moga-CHOP-14 Combination Therapy

By MedXY 09/18/2025

A phase 2 study demonstrated that combining mogamulizumab with CHOP chemotherapy improves progression-free survival in older patients with adult T-cell leukemia/lymphoma, highlighting a promising first-line option.

Clinical Updates Gastroenterology news Specialties

Targeting TL1A in IBD: Safety and Efficacy of Tulisokibart in Crohn’s Disease and Ulcerative Colitis—Emerging Phase 2 Data

By MedXY 08/02/2025

Phase 2 trials show anti-TL1A antibody tulisokibart offers potential efficacy and good tolerability in refractory Crohn’s disease and ulcerative colitis, with ongoing phase 3 studies to confirm findings.